Although some of the improvement is a result of prevention and screening, advances in technology and in chemotherapy and immunotherapy pharmaceuticals have been major driving forces in the decline in cancer-related death.
David C. Fryefield, MD
Advertisement
Articles by David C. Fryefield, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
3
Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC
4
Bispecific-Based Approaches Highlight Key Multiple Myeloma Data Set to Emerge at EHA 2026
5